DLAT is a promising prognostic marker and therapeutic target for

hepatocellular carcinoma: A comprehensive study based on public databases

Peng Zhang 1† , Jiang-hua Zhao 2† , Liu-Xia Yuan 3 , Lin-Ling Ju 3 , Hui-Xuan Wang 3 , Feng Wang 4 , Lin Chen 3* , Wei-Hua Cai 5*

* Correspondence:

Lin Chen

xiaobei227@sina.com

Wei-Hua Cai

cwhntsy@163.com

¹ Nantong Institute of Liver Disease, Department of Hepatobiliary Surgery, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.


² Medical School of Nantong University, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.

³ Nantong Institute of Liver Disease, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.

⁴ Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.


⁵ Department of Hepatobiliary Surgery, Nantong Third People's Hospital, Affiliated Nantong Hospital 3 of Nantong University, Nantong, China.

DLAT Association Result




Pearson Correlation Coefficient (Pearson test)


Supplementary Figure 1 The heatmap from the LinkedOmic database showed the all genes correlated with DLAT.




Supplementary Figure 2 Correlation between DLAT and immune infiltration was analyzed by MCPCOUNTER algorithm.



Supplementary Figure 3 Correlation between DLAT and immune infiltration was analyzed by QUANTISEQ algorithm.



Supplementary Figure 4 Correlation between DLAT and immune infiltration was analyzed by TIMER algorithm.



Supplementary Figure 5 The impact of DLAT expression on the OS of HCC patients with enriched or decreased infiltration ratios.